Cellectis Logo.png
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
October 19, 2021 16:30 ET | Cellectis Inc.
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing company with clinical-stage immuno-oncology programs using...
Cellectis Logo.png
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
October 12, 2021 16:35 ET | Cellectis Inc.
NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology programs using...
Cellectis Logo.png
Monthly information on share capital and company voting rights
September 10, 2021 16:30 ET | Cellectis Inc.
(Article 223-16 of General Regulation of the French financial markets authority) NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 ...
Cellectis Logo.png
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
July 29, 2021 16:34 ET | Cellectis Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a gene-editing platform company with clinical-stage immuno-oncology...
Cellectis Logo.png
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
July 29, 2021 16:34 ET | Cellectis Inc.
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ : CLLS – EURONEXT GROWTH : ALCLS) (la « Société »), une société d’édition du génome spécialisée dans les essais en immuno-oncologie...
Cellectis Logo.png
Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities
June 14, 2021 16:30 ET | Cellectis Inc.
• Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates...
Cellectis Logo.png
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
June 02, 2021 02:30 ET | Cellectis Inc.
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 1, 2021 at its head office in Paris, France. ...
Cellectis Logo.png
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T
May 11, 2021 16:30 ET | Cellectis Inc.
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop...
Cellectis Logo.png
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
May 06, 2021 16:30 ET | Cellectis Inc.
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical...
Cellectis Logo.png
Cellectis Completes Sale of $47 million through its ATM program
April 09, 2021 02:30 ET | Cellectis Inc.
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary...